NEW YORK (360Dx) – Laboratory Corporation of America and European clinical lab testing company Unilabs announced today a collaboration that will create a global network for developing and commercializing companion diagnostics.
The collaboration is intended to accelerate adoption of companion diagnostics by expanding commercialization channels for the assays in North America and Europe. The companies will globally harmonize processes to simplify technical, regulatory, and clinical complexities associated with the diagnostics. Terms of the deal were not disclosed.
The collaboration will initially focus on commercial availability of assays developed and validated analytically and clinically by LabCorp and Covance, its drug development business. The first application of the collaboration is expected to be in oncology, particularly immune-oncology.
"With this collaboration, we are capitalizing on the scientific and operational strength of two leaders in companion diagnostics to benefit biopharmaceutical clients who need global solutions for precision medicine, with the ultimate goal of improving health and improving lives for patients around the world," David King, LabCorp chairman and CEO, said in a statement.
Unilabs CEO Jos Lamers explained the global harmonization that the collaboration would create.
"Our combined ability to bridge the time gaps between development phase and drug approval, and to national reimbursement, by offering a centralized laboratory testing facility, gives our respective customers the advantage of early adoption of their drug," Lamers said, in a statement. "The intimate knowledge of local testing standards, regulatory and quality requirements, and navigating logistical challenges will ensure instant access to high-quality testing."